Immuneering Corp
IMRX · Pharmaceutical Preparations · 25.9M shares · +57%/yr ↑ dilution · EDGAR filings ↗
Reference price $4.56 · est. market cap ~$118M — last insider purchase, 2026-06-23 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — oncology clinical, very cash-rich.
Strengths
- Liquidity — current ratio 17.5 (94th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- High convictionHigh conviction — notable institutional holders, insider buying, and a strong balance sheet
- Cash burnNegative free cash flow (-45.5M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Exec changeRecent 8-K item 5.02 8-K ↗
- Chronic dilutionShare count +57%/yr over 4y (dilution, book value/share -77%)
- Insider buyingInsider buying — 7 open-market buy(s) by 6 insider(s) (cluster of 6 insiders, ~$270,336, last 6mo) Form 4 ↗
- Strong balance sheetStrong balance sheet — $129M cash & investments, ~11 quarters of runway
- Notable holderHeld by 5 notable fund(s): FMR LLC, CITADEL ADVISORS LLC, GOLDMAN SACHS GROUP INC +2 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-25.6%
Return on assets
-24.2%
Current ratio
17.5×
Free cash flow
-$45M
EBITDA
-$59M
Tangible book value
$211M
Cash & investments
$129M
Cash runway
11q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2026-06-23 | Zeskind Benjamin J. | Buy | 2.4K | $4.56 |
| 2026-06-15 | Hall Brett Matthew | Buy | 6.0K | $4.15 |
| 2026-03-13 | Neufeld Leah R | Grant | 3.6K | $4.29 |
| 2026-01-16 | Brakewood Harold Eugene | Buy | 5.2K | $4.76 |
| 2026-01-15 | Schall Thomas J. | Buy | 22K | $4.67 |
| 2026-01-15 | Hall Brett Matthew | Buy | 2.3K | $4.57 |
| 2026-01-13 | Neufeld Leah R | Buy | 2.6K | $4.15 |
| 2026-01-12 | Feinberg Peter | Buy | 20K | $4.35 |
| 2025-10-03 | Feinberg Peter | Buy | 7.5K | $6.67 |
| 2025-10-01 | Morales Mallory | Buy | 300 | $6.39 |
| 2025-10-01 | Neufeld Leah R | Buy | 800 | $6.38 |
| 2025-10-01 | Bookman Michael | Buy | 1.0K | $6.83 |
| 2025-09-30 | Feinberg Peter | Buy | 7.5K | $7.03 |
| 2025-09-29 | Feinberg Peter | Buy | 5.0K | $7.18 |
| 2025-09-15 | Neufeld Leah R | Grant | 12K | $1.43 |
| 2025-09-15 | Morales Mallory | Grant | 14K | $1.43 |
| 2025-09-15 | Hall Brett Matthew | Grant | 15K | $1.43 |
| 2025-07-02 | Zeskind Benjamin J. | Buy | 7.0K | $3.53 |
| 2025-07-02 | HAUSMAN DIANA | Buy | 3.0K | $3.62 |
| 2025-07-02 | Neufeld Leah R | Buy | 700 | $3.57 |
| 2025-07-02 | HAUSMAN DIANA | Buy | 2.5K | $3.60 |
| 2025-07-01 | Zeskind Benjamin J. | Buy | 3.0K | $3.38 |
| 2025-06-27 | Schall Thomas J. | Buy | 9.5K | $3.66 |
| 2025-06-23 | Hall Brett Matthew | Buy | 6.0K | $2.43 |
| 2025-06-20 | Hall Brett Matthew | Buy | 7.4K | $2.70 |
| 2025-06-20 | Brakewood Harold Eugene | Buy | 1.9K | $2.53 |
| 2025-06-18 | Feinberg Peter | Buy | 25K | $2.53 |
| 2025-06-18 | Zeskind Benjamin J. | Buy | 21K | $2.39 |
| 2025-06-17 | Schall Thomas J. | Buy | 40K | $2.21 |
All non-derivative Form 4 activity (SEC), newest first.
Notable events (8-K)
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-06-15 | 2026-06-11 | 0001790340-26-000074 ↗ |
| 8-K | 2026-06-11 | 2026-06-11 | 0001790340-26-000062 ↗ |
| 8-K | 2026-06-01 | 2026-06-01 | 0001790340-26-000059 ↗ |
| 10-Q | 2026-05-15 | 2026-03-31 | 0001790340-26-000057 ↗ |
| 8-K | 2026-05-15 | 2026-05-15 | 0001790340-26-000055 ↗ |
| 8-K | 2026-03-06 | 2026-03-06 | 0001790340-26-000040 ↗ |
| 10-K | 2026-03-06 | 2025-12-31 | 0001790340-26-000042 ↗ |
| 8-K | 2026-01-07 | 2026-01-07 | 0001790340-26-000006 ↗ |
| 8-K | 2025-11-12 | 2025-11-12 | 0001790340-25-000133 ↗ |
| 10-Q | 2025-11-12 | 2025-09-30 | 0001790340-25-000135 ↗ |
| 8-K | 2025-09-25 | 2025-09-24 | 0001104659-25-093436 ↗ |
| 8-K | 2025-09-24 | 2025-09-24 | 0001104659-25-092957 ↗ |